Pharsight

Neupro patents expiration

NEUPRO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617591 UCB INC Transdermal delivery system for the administration of rotigotine
Jul, 2023

(2 months ago)

US8246980 UCB INC Transdermal delivery system
Nov, 2025

(2 years from now)

US8246979 UCB INC Transdermal delivery system for the administration of rotigotine
Sep, 2027

(3 years from now)

US10350174 UCB INC Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
Dec, 2030

(7 years from now)

US10130589 UCB INC Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
Dec, 2030

(7 years from now)

US9925150 UCB INC Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
Mar, 2032

(8 years from now)

Neupro is owned by Ucb Inc.

Neupro contains Rotigotine.

Neupro has a total of 6 drug patents out of which 1 drug patent has expired.

Expired drug patents of Neupro are:

  • US8617591

Neupro was authorised for market use on 09 May, 2007.

Neupro is available in film, extended release;transdermal dosage forms.

Neupro can be used as treatment of signs and symptoms of parkinson's disease by application of claimed transdermal system; treatment of restless legs syndrome by application of claimed transdermal delivery system, a method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient.

The generics of Neupro are possible to be released after 01 March, 2032.

Drugs and Companies using ROTIGOTINE ingredient

Market Authorisation Date: 09 May, 2007

Treatment: A method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient; Treatment of s...

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

How can I launch a generic of NEUPRO before it's drug patent expiration?
More Information on Dosage

NEUPRO family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic